Non-Small Cell Lung Cancer

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

The China-only study reported a statistically significant overall survival gain but also higher rates of bleeding and serious adverse events, leaving regulators and investors to await global trial data to judge wider use.